Projects funded by the NCN
Involvement of astrocytes in the neuroprotective mechanism evoked by enhancement of noradrenergic transmission in trasngenic mouse model of progressive parkinsonism.
2019/35/N/NZ7/03300
Keywords:
astrocytes neuroprotection neurodegeneration Parkinson's disease transgenic models CRISPR/Cas9
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- NZ3_5: Molecular neurobiology
- NZ5_3: Pathogenesis of human diseases
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk
woj.
Principal investigator (from the host institution):
Number of co-investigators in the project: 3
Call: PRELUDIUM 18 - announced on 2019-09-16
Amount awarded: 139 500 PLN
Project start date (Y-m-d): 2020-07-22
Project end date (Y-m-d): 2024-07-21
Project duration:: 48 months (the same as in the proposal)
Project status: Project completed
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Articles in post-conference publications (4)
- Exploitation of in-vitro and in-vivo models characterized by enhancement of astrocytes upon noradrenergic targeting for study of presymptomatic Parkinson's diseaseAuthors:J. Barut, K. Rafa-Zablocka, A. Jurga, M. Baginska, I. Nalepa, R. Parlato, G. KreinerConference:European Neuropsychopharmacology 53 (2021) S585–S672 (rok: 2021, tom: 34th ECNP Congress, strony: https://www.ecnp.eu/Congress2021/ECNPcongress), Wydawca: European NeuropsychopharmacologyData:konferencja 2-5.10.2021Status:PublishedDOI:10.718 - link to the publication
- Exploitation of in-vitro and in-vivo models characterized by enhancement of astrocytes upon noradrenergic targeting for study of presymptomatic Parkinson's diseaseAuthors:J. Barut, K. Rafa-Zablocka, A. Jurga, M. Baginska, I. Nalepa, R. Parlato, G. KreinerConference:European Neuropsychopharmacology 53 (2021) S585–S672 (rok: 2021, tom: 34th ECNP Congress, strony: https://www.ecnp.eu/Congress2021/ECNPcongress), Wydawca: European NeuropsychopharmacologyData:konferencja 2-5.10.2021Status:PublishedDOI:10.718 - link to the publication
- Examination of the relevance of noradrenergic transmission in astrocytes in in vitro and in vivomodels of presymptomatic Parkinson's diseaseAuthors:J. Barut, K. Rafa-Zabłocka, M. Wilczkowski, K. Maziarz, P. Chmielarz, R. Parlato, G. KreinerConference:GliaVolume 71: XVI European Meeting on Glial Cells in Health and Disease, Berlin, July 8–11, 2023 (rok: 2023, tom: XVI European Meeting on Glial Cells in Health and Disease, strony: https://onlinelibrary.wiley.com/), Wydawca: GliaData:konferencja 8-11.07.2023r.Status:PublishedDOI:10.1002/glia.24419 - link to the publication
- Exploitation of in-vitro and in-vivo models characterized by enhancement of astrocytes upon noradrenergic targeting for study of presymptomatic Parkinson's diseaseAuthors:J. Barut, K. Rafa-Zablocka, A. Jurga, M. Baginska, I. Nalepa, R. Parlato, G. KreinerConference:European Neuropsychopharmacology 53 (2021) S585–S672 (rok: 2021, tom: 34th ECNP Congress, strony: https://www.ecnp.eu/Congress2021/ECNPcongress), Wydawca: European NeuropsychopharmacologyData:konferencja 2-5.10.2021Status:PublishedDOI:10.718 - link to the publication